Watson gets conditional US approval to buy Actavis
Watson Pharmaceuticals has won US antitrust approval to buy Swiss firm Actavis Inc but only with certain conditions, the Federal Trade Commission (FTC) announced yesterday.
Watson Pharmaceuticals and Actavis will need to sell the rights and assets to 18 drugs to Sandoz International and Par Pharmaceuticals, in addition to relinquishing the manufacturing and marketing rights to three others.
The $5.9 billion acquisition of Actavis would be otherwise uncompetitive, according to the FTC. The decision is part of the FTC’s ongoing effort to keep treatment prices low and quality and choice of products and services high for US consumers, by promoting competition in the health care sector.
The FTC’s Health Care Work (The Federal Trade Commission)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.